000908 ST景峰医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.348-154.1652,684.856-500.552-54.114
总资产报酬率 ROA (%)0.220-9.19215.228-18.754-7.585
投入资产回报率 ROIC (%)0.318-20.45323.837-30.059-11.048

边际利润分析
销售毛利率 (%)69.24362.88962.80071.75876.288
营业利润率 (%)5.989-15.33749.004-26.322-8.127
息税前利润/营业总收入 (%)7.499-12.59049.229-23.423-4.084
净利润/营业总收入 (%)4.381-20.90638.326-34.626-11.331

收益指标分析
经营活动净收益/利润总额(%)71.92483.734-31.53569.97558.938
价值变动净收益/利润总额(%)-2.985-46.696159.891-14.854-16.140
营业外收支净额/利润总额(%)5.04225.270-23.91511.15620.220

偿债能力分析
流动比率 (X)4.4730.3440.2510.2050.527
速动比率 (X)4.3930.2950.2020.1430.416
资产负债率 (%)18.859103.445101.610116.47086.166
带息债务/全部投入资本 (%)0.85559.23978.67392.29570.987
股东权益/带息债务 (%)11,403.41922.81916.776-11.59825.432
股东权益/负债合计 (%)440.8822.7298.564-5.70513.121
利息保障倍数 (X)6.293-1.5875.084-3.775-0.669

营运能力分析
应收账款周转天数 (天)43.97350.76360.09167.16879.197
存货周转天数 (天)100.879106.486126.489179.444249.019